Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C-A population-based cohort study

Tsai HY, Chang HP, Chen CJ, Hsu WL, Huang LY, Lee PC
Record ID 32018002657
English
Original Title: Effects of direct-acting antiviral therapy for patients with advanced hepatocellular carcinoma and concomitant hepatitis C - A population-based cohort study
Authors' objectives: We analyzed real-world data to elucidate the effects of anti-Hepatitis C virus (HCV) direct-acting antiviral (DAA) therapy on survival in patients with advanced hepatocellular carcinoma (HCC) and concomitant HCV infection treated with sorafenib.
Authors' results and conclusions: The analysis of big data from the Taiwan National Health Insurance Research Database revealed that advanced HCC patients on sorafenib benefited from DAAs as a treatment for HCV infection. Patients whose HCV infection was cured had better OS.
Authors' recommendations: The effects of DAA treatment on the survival of patients with advanced HCC and concomitant HCV infection were investigated by analyzing big data from the NHI database in Taiwan. The results indicated that advanced HCC patients who received sorafenib achieved survival benefits from the use of DAAs as treatment for HCV infection, with patients whose HCV infection had been cured having better OS.
Authors' methods: This population-based retrospective cohort study used the Taiwan National Health Insurance Research Database and the Registration System for Patients Treated with Oral Hepatitis C Antivirals to identify patients with advanced HCC and concomitant HCV infection who received initial targeted therapy (sorafenib) in 2018-2019. The overall survival (OS) of the DAA and non-DAA groups were compared using the Kaplan-Meier survival analysis. Propensity score matching was performed using a ratio of 1:4 to reduce confounding between the DAA and non-DAA groups.
Details
Project Status: Completed
Year Published: 2021
URL for published report: https://www.europeanreview.org/article/27454
URL for additional information: English (Abstract and published paper) ; Full HTA report in Chinese (Mandarin)
English language abstract: An English language summary is available
Publication Type: Full HTA
Pubmed ID: 34919256
DOI: 10.26355/eurrev_202112_27454
MeSH Terms
  • Carcinoma, Hepatocellular
  • Liver Neoplasms
  • Antiviral Agents
  • Hepatitis C, Chronic
  • Sorafenib
  • Antineoplastic Agents
Keywords
  • Advanced hepatocellular carcinoma (HCC)
  • Direct-acting antiviral (DAA)
  • Survival
  • Propensity score matching.
Contact
Organisation Name: Center for Drug Evaluation
Contact Address: 3F.,No.465, Sec.6, Zhongxiao E. Rd., Taipei 11557, Taiwan. R.O.C.
Contact Name: Li Ying (Grace) Huang
Contact Email: lyhuang277@cde.org.tw
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.